B-cell responses to HIV infection

Immunological Reviews

Volumn 275, Issue 1, 2017, Pages 33-48

  Moir, Susan ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

B cells; HIV; HIV specific humoral immunity; pathogenesis; persisting viremia

Indexed keywords

GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; LYMPHOID TISSUE; MEMORY CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLASMA CELL; PLASMABLAST; PRIORITY JOURNAL; REVIEW; VIREMIA; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; VIROLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY-PRODUCING CELLS; B-LYMPHOCYTES; HIV; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY;

EID: 85010869940     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12502     Document Type: Review

References (173)

1. Burton DR, Ahmed R, Barouch DH, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012;12:396–407.
2. Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015;125:2203–2210.
3. Benitez A, Weldon AJ, Tatosyan L, et al. Differences in mouse and human nonmemory B cell pools. J Immunol. 2014;192:4610–4619.
4. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A. 2006;103:2262–2267.
5. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol. 2001;167:3610–3618.
6. Meffre E, Davis E, Schiff C, et al. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol. 2000;1:207–213.
7. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105:4390–4398.
8. + T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood. 2007;109:2086–2088.
9. Palanichamy A, Barnard J, Zheng B, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009;182:5982–5993.
10. Saifi M, Wysocki CA. Autoimmune Disease in Primary Immunodeficiency: At the Crossroads of Anti-Infective Immunity and Self-Tolerance. Immunol Allergy Clin North Am. 2015;35:731–752.
11. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309:453–458.
12. Moir S, Malaspina A, Pickeral OK, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med. 2004;200:587–599.
13. van Grevenynghe J, Cubas RA, Noto A, et al. Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest. 2011;121:3877–3888.
14. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205:1797–1805.
15. Levesque MC, Moody MA, Hwang KK, et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009;6:e1000107.
16. + memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013;39:758–769.
17. Pallikkuth S, Pilakka Kanthikeel S, Silva SY, et al. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol. 2011;186:6173–6181.
18. Cubas RA, Mudd JC, Savoye AL, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med. 2013;19:494–499.
19. Dolcetti R, Gloghini A, Caruso A, Carbone A. A lymphomagenic role for HIV beyond immune suppression? Blood. 2016;127:1403–1409.
20. Kardava L, Moir S, Shah N, et al. Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. J Clin Invest. 2014;124:3252–3262.
21. Mouquet H. Antibody B cell responses in HIV-1 infection. Trends Immunol. 2014;35:549–561.
22. Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 2006;108:1580–1587.
23. Hart M, Steel A, Clark SA, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J. Immunol. 2007;178:8212–8220.
24. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116:5571–5579.
25. Wheatley AK, Kristensen AB, Lay WN, Kent SJ. HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation. Sci Rep. 2016;6:26478.
26. Ho J, Moir S, Malaspina A, et al. Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc Natl Acad Sci USA. 2006;103:19436–19441.
27. Lundstrom W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Semin Immunol. 2012;24:218–224.
28. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308:1906–1908.
29. Verkoczy L, Diaz M. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS. 2014;9:224–234.
30. Moir S, Malaspina A, Li Y, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med. 2000;192:637–646.
31. Heesters BA, Lindqvist M, Vagefi PA, et al. Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes. PLoS Pathog. 2015;11:e1005285.
32. Jelicic K, Cimbro R, Nawaz F, et al. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-beta1 production and FcRL4 expression. Nat Immunol. 2013;14:1256–1265.
33. Xu W, Santini PA, Sullivan JS, et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol. 2009;10:1008–1017.
34. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature. 2003;424:213–219.
35. van Zelm MC, Szczepanski T, van der Burg M, van Dongen JJ. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med. 2007;204:645–655.
36. Berkowska MA, Driessen GJ, Bikos V, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood. 2011;118:2150–2158.
37. De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015;15:137–148.
38. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15:160–171.
39. Weisel FJ, Zuccarino-Catania GV, Chikina M, Shlomchik MJ. A temporal switch in the germinal center determines differential output of memory B and plasma cells. Immunity. 2016;44:116–130.
40. Perez-Shibayama C, Gil-Cruz C, Ludewig B. Plasticity and complexity of B cell responses against persisting pathogens. Immunol Lett. 2014;162:53–58.
41. Amu S, Ruffin N, Rethi B, Chiodi F. Impairment of B-cell functions during HIV-1 infection. AIDS. 2013;27:2323–2334.
42. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev. 2013;254:207–224.
43. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol. 2012;12:709–719.
44. Tarlinton D, Good-Jacobson K. Diversity among memory B cells: origin, consequences, and utility. Science. 2013;341:1205–1211.
45. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998;188:1679–1689.
46. + B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol. 2006;177:3728–3736.
47. Thorarinsdottir K, Camponeschi A, Gjertsson I, Martensson IL. CD21 -/low B cells: A Snapshot of a Unique B Cell Subset in Health and Disease. Scand J Immunol. 2015;82:254–261.
48. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15:149–159.
49. Ehrhardt GR, Hsu JT, Gartland L, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med. 2005;202:783–791.
50. Wherry EJ, Ha SJ, Kaech SM, et al. Molecular Signature of CD8(+) T Cell Exhaustion during Chronic Viral Infection. Immunity. 2007;27:670–684.
51. Rubtsova K, Rubtsov AV, Cancro MP, Marrack P. Age-Associated B Cells: A T-bet-Dependent effector with roles in protective and pathogenic immunity. J Immunol. 2015;195:1933–1937.
52. Scheid JF, Mouquet H, Feldhahn N, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2009;343:65–67.
53. Meffre E, Louie A, Bannock J, et al. Maturational characteristics of HIV-specific antibodies in viremic individuals. JCI Insight. 2016;1:e84610.
54. Odendahl M, Mei H, Hoyer BF, et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood. 2005;105:1614–1621.
55. Fink K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections. Front Immunol. 2012;3:78.
56. Li CK, Rappuoli R, Xu XN. Correlates of protection against influenza infection in humans–on the path to a universal vaccine? Curr Opin Immunol. 2013;25:470–476.
57. Good-Jacobson KL, O'Donnell K, Belz GT, Nutt SL, Tarlinton DM. c-Myb is required for plasma cell migration to bone marrow after immunization or infection. J Exp Med. 2015;212:1001–1009.
58. Buckner CM, Moir S, Ho J, et al. Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation. J Virol. 2013;87:5800–5811.
59. Liao HX, Chen X, Munshaw S, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med. 2011;208:2237–2249.
60. Mei HE, Yoshida T, Sime W, et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood. 2009;113:2461–2469.
61. Lindqvist M, van Lunzen J, Soghoian DZ, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest. 2012;122:3271–3280.
62. Buckner CM, Moir S, Kardava L, et al. CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammation. J Allergy Clin Immunol. 2014;133(1676–1685):e1675.
63. Nilssen DE, Oktedalen O, Brandtzaeg P. Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy. Gut. 2004;53:487–493.
64. Blink EJ, Light A, Kallies A, Nutt SL, Hodgkin PD, Tarlinton DM. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J Exp Med. 2005;201:545–554.
65. Tangye SG. Staying alive: regulation of plasma cell survival. Trends Immunol. 2011;32:595–602.
66. Olteanu H. Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. Surg Pathol Clin. 2016;9:101–116.
67. Tipton CM, Fucile CF, Darce J, et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol. 2015;16:755–765.
68. Halliley JL, Tipton CM, Liesveld J, et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity. 2015;43:132–145.
69. Montezuma-Rusca JM, Moir S, Kardava L, et al. Bone Marrow Plasma cells Are a Primary Source of Serum HIV-1-Specific Antibodies in Chronically Infected Individuals. J Immunol. 2015;194:2561–2568.
70. Ost A, Baroni CD, Biberfeld P, et al. Lymphadenopathy in HIV infection: histological classification and staging. APMIS Suppl. 1989;8:7–15.
71. Pallesen G, Gerstoft J, Mathiesen L. Stages in LAV/HTLV-III lymphadenitis. I. Histological and immunohistological classification. Scand J Immunol. 1987;25:83–91.
72. Naradikian MS, Hao Y, Cancro MP. Age-associated B cells: key mediators of both protective and autoreactive humoral responses. Immunol Rev. 2016;269:118–129.
73. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods. 2004;286:111–122.
74. Pinto D, Montani E, Bolli M, et al. A functional BCR in human IgA and IgM plasma cells. Blood. 2013;121:4110–4114.
75. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94–96.
76. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012;37:412–425.
77. Scheid JF. HIV-specific B cell response in patients with broadly neutralizing serum activity. Science. 2015;350:1175.
78. Moir S, Malaspina A, Fauci AS. Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol. 2011;18:1317–1321.
79. Dosenovic P, Chakrabarti B, Soldemo M, et al. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J Immunol. 2009;183:3373–3382.
80. Morris L, Chen X, Alam M, et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS ONE. 2011;6:e23532.
81. Wheatley AK, Whittle JR, Lingwood D, et al. H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. J Immunol. 2015;195:602–610.
82. Franz B, May KF Jr, Dranoff G, Wucherpfennig K. Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood. 2011;118:348–357.
83. Whittle JR, Wheatley AK, Wu L, et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol. 2014;88:4047–4057.
84. Muellenbeck MF, Ueberheide B, Amulic B, et al. Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med. 2013;210:389–399.
85. Cox KS, Tang A, Chen Z, et al. Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures. MAbs. 2016;8:129–140.
86. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE Jr. Immunodominance of the VH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones. J Immunol. 2008;180:3279–3288.
87. Scherer EM, Smith RA, Simonich CA, Niyonzima N, Carter JJ, Galloway DA. Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog. 2014;10:e1004461.
88. Li Y, O'Dell S, Wilson R, et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol. 2012;86:11231–11241.
89. Lynch RM, Tran L, Louder MK, et al. The development of CD4 binding site antibodies during HIV-1 infection. J Virol. 2012;86:7588–7595.
90. Fitzgerald W, Grivel JC. A universal nanoparticle cell secretion capture assay. Cytometry A. 2013;83:205–211.
91. Haynes BF. New approaches to HIV vaccine development. Curr Opin Immunol. 2015;35:39–47.
92. Sok D, van Gils MJ, Pauthner M, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A. 2014;111:17624–17629.
93. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333:1633–1637.
94. Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333:1593–1602.
95. Sundling C, Li Y, Huynh N, et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med. 2012;4:142ra196.
96. Amadori A, Zamarchi R, Ciminale V, et al. HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. J Immunol. 1989;143:2146–2152.
97. Bussmann BM, Reiche S, Bieniek B, Krznaric I, Ackermann F, Jassoy C. Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV. Virology. 2010;397:7–13.
98. Fondere JM, Huguet MF, Yssel H, et al. Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy. AIDS. 2003;17:2323–2330.
99. Corti D, Langedijk JP, Hinz A, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE. 2010;5:e8805.
100. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466–470.
101. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285–289.
102. Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509:55–62.
103. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491:406–412.
104. Huang J, Kang BH, Pancera M, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515:138–142.
105. Huang J, Doria-Rose NA, Longo NS, et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat Protoc. 2013;8:1907–1915.
106. Corti D, Lanzavecchia A. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol Spectr. 2014;2:AID-0018-2014.
107. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK. Different B cell populations mediate early and late memory during an endogenous immune response. Science. 2011;331:1203–1207.
108. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis. 2010;10:499–503.
109. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–1879.
110. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008;82:12449–12463.
111. Yates NL, Lucas JT, Nolen TL, et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS. 2011;25:2089–2097.
112. Budeus B, Schweigle de Reynoso S, Przekopowitz M, Hoffmann D, Seifert M, Kuppers R. Complexity of the human memory B-cell compartment is determined by the versatility of clonal diversification in germinal centers. Proc Natl Acad Sci USA. 2015;112:E5281–E5289.
113. Wirths S, Lanzavecchia A. ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur J Immunol. 2005;35:3433–3441.
114. Correia IR. Stability of IgG isotypes in serum. MAbs. 2010;2:221–232.
115. Yates NL, Liao HX, Fong Y, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6:228ra239.
116. Chung AW, Kumar MP, Arnold KB, et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell. 2015;163:988–998.
117. Trama AM, Moody MA, Alam SM, et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014;16:215–226.
118. Williams WB, Liao HX, Moody MA, et al. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015;349:aab1253.
119. Muster T, Guinea R, Trkola A, et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol. 1994;68:4031–4034.
120. Stiegler G, Kunert R, Purtscher M, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2001;17:1757–1765.
121. Brink R. The imperfect control of self-reactive germinal center B cells. Curr Opin Immunol. 2014;28:97–101.
122. Jarossay A, Hadzhieva M, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. Natural and Induced Antibody Polyreactivity. Anticancer Agents Med Chem. 2015;15:1230–1241.
123. Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467:591–595.
124. Liu M, Yang G, Wiehe K, et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol. 2015;89:784–798.
125. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576.
126. Doria-Rose NA, Klein RM, Daniels MG, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010;84:1631–1636.
127. Piantadosi A, Panteleeff D, Blish CA, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol. 2009;83:10269–10274.
128. + T cell decline and high viral load during acute infection. J Virol. 2011;85:4828–4840.
129. Landais E, Huang X, Havenar-Daughton C, et al. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathog. 2016;12:e1005369.
130. + T cell responses. J Virol. 2015;90:2208–2220.
131. Tomaras GD, Binley JM, Gray ES, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011;85:11502–11519.
132. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458:636–640.
133. Mouquet H, Klein F, Scheid JF, et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE. 2011;6:e24078.
134. Wu X, Zhang Z, Schramm CA, et al. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell. 2015;161:470–485.
135. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469–476.
136. Bhiman JN, Anthony C, Doria-Rose NA, et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015;21:1332–1336.
137. Moore PL, Gray ES, Sheward D, et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011;85:3128–3141.
138. Schoofs T, Klein F, Braunschweig M, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352:997–1001.
139. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856–861.
140. Zhou T, Lynch RM, Chen L, et al. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell. 2015;161:1280–1292.
141. Euler Z, van Gils MJ, Bunnik EM, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis. 2010;201:1045–1053.
142. Moore PL, Williamson C, Morris L. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 2015;23:204–211.
143. de Bree GJ, Lynch RM. B cells in HIV pathogenesis. Curr Opin Infect Dis. 2016;29:23–30.
144. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008;197:572–579.
145. Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A. 2009;106:7939–7944.
146. Johannesson TG, Sogaard OS, Tolstrup M, et al. The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults. PLoS ONE. 2012;7:e42307.
147. Fontaine J, Chagnon-Choquet J, Valcke HS, et al. High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood. 2011;117:145–155.
148. Fournier AM, Baillat V, Alix-Panabieres C, et al. Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. AIDS. 2002;16:1755–1760.
149. Cagigi A, Palma P, Nilsson A, et al. The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children. AIDS. 2010;24:2075–2080.
150. Ghosh S, Feyen O, Jebran AF, et al. Memory B cell function in HIV-infected children-decreased memory B cells despite ART. Pediatr Res. 2009;66:185–190.
151. Muema DM, Macharia GN, Hassan AS, et al. Control of viremia enables acquisition of resting memory B cells with age and normalization of activated B cell phenotypes in HIV-infected children. J Immunol. 2015;195:1082–1091.
152. Longwe H, Gordon S, Malamba R, French N. Characterising B cell numbers and memory B cells in HIV infected and uninfected Malawian adults. BMC Infect Dis. 2010;10:280.
153. Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS. 2005;19:1947–1955.
154. Ferreira CB, Merino-Mansilla A, Llano A, et al. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations. J Virol. 2013;87:12227–12236.
155. + T-cell counts. J Acquir Immune Defic Syndr. 2011;57:e56–e58.
156. Amos JD, Wilks AB, Fouda GG, et al. Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. J Virol. 2013;87:11121–11134.
157. Gach JS, Achenbach CJ, Chromikova V, et al. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS ONE. 2014;9:e85371.
158. Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat Immunol. 2015;16:563–570.
159. Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013;13:487–498.
160. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998;188:233–245.
161. Guan Y, Sajadi MM, Kamin-Lewis R, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A. 2009;106:3952–3957.
162. Buckner CM, Kardava L, Zhang X, et al. Maintenance of HIV-specific memory B-cell responses in elite controllers despite low viral burdens. J Infect Dis. 2016;214:390–398.
163. Zhang Y, Garcia-Ibanez L, Toellner KM. Regulation of germinal center B-cell differentiation. Immunol Rev. 2016;270:8–19.
164. Petrovas C, Yamamoto T, Gerner MY, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest. 2012;122:3281–3294.
165. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol. 2012;188:3247–3256.
166. Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med. 2013;210:143–156.
167. Cubas R, Perreau M. The dysfunction of T follicular helper cells. Curr Opin HIV AIDS. 2014;9:485–491.
168. Moir S, Fauci AS. B-cell exhaustion in HIV infection: the role of immune activation. Curr Opin HIV AIDS. 2014;9:472–477.
169. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–499.
170. Petrovas C, Koup RA. T follicular helper cells and HIV/SIV-specific antibody responses. Curr Opin HIV AIDS. 2014;9:235–241.
171. + helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J Virol. 2014;88:13310–13321.
172. Boswell KL, Paris R, Boritz E, et al. Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. PLoS Pathog. 2014;10:e1003853.
173. Nabi G, Genannt Bonsmann MS, Tenbusch M, et al. GagPol-specific CD4(+) T-cells increase the antibody response to Env by intrastructural help. Retrovirology. 2013;10:117.